Mergers and Acquisitions
Dimethaid Research completes purchase agreement for Oxo Chemie AG
Published in Hepatitis Weekly, June 10th, 2002
This US$36.96 million acquisition will expand its existing product pipeline to include a new immune-regulating platform drug, known as WF10, currently in development for the treatment of AIDS and hepatitis C.
Under the terms of the purchase agreement, $500,000 in cash is payable on closing (scheduled for May 31, 2002) and a further $500,000 cash payment is due in November 2002. Additional payments of $4.0 million in November 2002, $4.24 million in November 2003 and $9.24 million in each of November 2004, 2005 and 2006, may be made in any...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2002-06-10)
More Articles from Hepatitis Weekly
- Cirrhosis
HLA compatibility impacts outcomes in hepatitis B related liver transplantation - Coinfection
Protease inhibitors may reduce hepatitis C load in people coinfected with HIV - Chronic Hepatitis B
Combination of vaccine and antiviral fractures immune tolerance in virus model - Combination Therapy
RNA levels at 12 weeks best indicator for sustained response in hepatitis C - Osteoporosis
Vitamin K-2 prevents bone loss in women with cirrhosis - End-stage Liver Disease
Potential therapy reported for children, adults - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
